Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
606 people get VPHM articles and Market Currents by email alert.
Get email alerts on VPHM »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
PR Newswire (May 9, 2013)
-
-
-
PR Newswire (Apr 25, 2013)
-
-
-
PR Newswire (Feb 27, 2013)
-
PR Newswire (Feb 22, 2013)
-
PR Newswire (Feb 11, 2013)
-
The Upward Climb Of Halozyme TherapeuticsJohn Eastman • Mon, Jan 14 -
PR Newswire (Jan 7, 2013)
-
Halozyme Therapeutics Set To Shine On Deal With PfizerPropThink • Fri, Dec 21, 2012
-
PR Newswire (Dec 12, 2012)
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
ViroPharma And Generic Vancocin: A Contentious IssueTheodore Cohen • Wed, Apr 11, 2012
-
-
Something to Like About ViroPharma: Management Stock OwnershipNakedValue • Sun, Apr 24, 2011 -
-
ViroPharma Finally Able to Look ForwardEP Vantage • Thu, Aug 6, 2009 -
-
-
-
Viropharma's Antiviral Bombs: Here We Go AgainDerek Lowe • Tue, Feb 10, 2009 -
-
-
-
-
-
-
ViroPharma: Still ImpressiveHilary Kramer • Tue, Apr 3, 2007
-
-
-
The Upward Climb Of Halozyme TherapeuticsJohn Eastman • Mon, Jan 14
-
Halozyme Therapeutics Set To Shine On Deal With PfizerPropThink • Fri, Dec 21, 2012
-
Dyax And ViroPharma: An Overview Of HAE SpaceLifeSci Advisors • Tue, Sep 18, 2012 -
-
-
-
-
-
-
6 Analyst Backed Small Cap Biotech Stocks With Plenty Of Cash CashZetaKap • Fri, Aug 3, 2012
-
-
-
-
-
-
3 Cash-Hoarding Biotech Stocks With Solid ProfitsZetaKap • Wed, Jul 4, 2012
-
-
-
ViroPharma Management Discusses Q3 2012 Results - Earnings Call TranscriptFri, Oct 26, 2012 • 2 Comments
-
ViroPharma's CEO Discusses Q2 2012 Results - Earnings Call TranscriptFri, Aug 10, 2012
-
ViroPharma Incorporated Q3 2009 Earnings Call TranscriptWed, Oct 28, 2009
-
ViroPharma Incorporated Q1 2009 Earnings Call TranscriptWed, Apr 29, 2009
-
ViroPharma, Inc., Q4 2008 Earnings Call TranscriptTue, Feb 24, 2009
-
ViroPharma Incorporated Q3 2008 Earnings Call TranscriptWed, Oct 29, 2008
-
ViroPharma Incorporated Q2 2008 Earnings Call TranscriptMon, Aug 25, 2008
-
ViroPharma Incorporated Q1 2008 Earnings Call TranscriptWed, May 28, 2008
-
ViroPharma Incorporated Q4 2007 Earnings Call TranscriptMon, Mar 10, 2008
-
PR Newswire (May 9, 2013)
-
PR Newswire (Apr 25, 2013)
-
at CNBC.com (Apr 17, 2013)
-
at CNBC.com (Apr 16, 2013)
-
at CNBC.com (Mar 8, 2013)
-
PR Newswire (Feb 27, 2013)
-
PR Newswire (Feb 22, 2013)
-
PR Newswire (Feb 11, 2013)
-
at MarketWatch.com (Jan 15, 2013)
-
PR Newswire (Jan 7, 2013)
-
PR Newswire (Dec 12, 2012)
-
PR Newswire (Nov 29, 2012)
-
PR Newswire (Nov 8, 2012)
-
PR Newswire (Oct 25, 2012)
-
PR Newswire (Oct 22, 2012)
-
PR Newswire (Oct 18, 2012)
VPHM vs. ETF Alternatives
Company Description
ViroPharma Incorporated and subsidiaries is a global biotechnology company dedicated to the development and commercialization of products that address serious diseases, with a focus on products used by physician specialists or in hospital settings. We have two marketed products and two... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Monday, January 23, 2012, 3:48 PM Part of J.P. Morgan's biotech (IBB -0.5%) cuts after the sector's recent run (I, II) include a move to Neutral from Overweight on Allos Therapeutics (ALTH +1.2%), noting that EU approval of its lymphoma drug looks at risk following last week's negative opinion from a European panel. Morgan's other calls lowered AMAG -6%, ACOR -0.5%, AMGN -2.5% and VPHM -2.4%. Comment! [Healthcare, On the Move]
- Monday, January 23, 2012, 9:53 AM Shares of AMAG Pharmaceuticals (AMG -4.4%) move lower after the firm takes on a downgrade from JPMorgan to Underweight. The ratings move on AMAG is part of a larger sector call that includes VPHM, ACOR, AMGN, and ALTH all getting slashed on valuation. Comment! [On the Move, Healthcare]
- Thursday, January 5, 2012, 5:14 PM ViroPharma (VPHM) says it expects 2012 sales to be above Street estimates, now expecting net product sales of $600M - $660M. The analyst consensus is for total revenue of $593M. Shares +4.8% AH. Comment! [Healthcare, On the Move]
- Wednesday, December 14, 2011, 3:30 PM Shares of ViroPharma (VPHM +15%) skyrocket after the biotech company announces approval of new labeling for its Vancocin capsules made effective through FDA approval of its supplemental new drug application. As a result, VPHM believes Vancocin will enjoy three years of exclusivity, and that generic vancomycin capsules will not be approved during this period. Comment! [Healthcare, On the Move]
- Wednesday, May 11, 2011, 8:50 AM Halozyme Therapeutics (HALO) +5% premarket after announcing an $83M global licensing agreement with ViroPharma (VPHM) to develop subcutaneous cinryze. (PR) Comment! [Healthcare, On the Move]
-
ZetaKap
3 Cash-Hoarding Biotech Stocks With Solid Profits http://bit.ly/LZCLlS $OMPI $SSRX $VPHM @ZetaKap - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Michael Kudrna
$VPHM acting healthy near trendline support today. No position but does look like a favorable trade if you want to buy before EU news $$ - View all 4 replies
-
Michael Kudrna: I'm playing a modest position in SIRI and as it nears my stop loss, I'd double down on it for low risk-high reward trdae
-
Michael Kudrna: but really I dont want to gamble on tomorrow. Im waiting for the news first, then Ill trade aggressively long if it acts healthy
-
Jim Van Meerten
VPHM - 96% Barchart technical buy signal - 15 new highs and up 19.98% in the last month - Relative Strength Index 68.83% and rsing - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Growth Stock Analytics
http://bit.ly/aLho79 Timely Top-ranked breakouts for December 20 - $VPHM, $MDSO, $WLP, $R, $SILC, $HELE, $IPXL, $XXIA. - View all 0 replies
-
MagicDiligence
ViroPharma $VPHM up 8%, another good CTL. Cinryze growing gangbusters and still little competition for Vancocin. http://bit.ly/c6BZdQ - View all 0 replies
LATEST REPLIES